更新于：2024-11-04
Estazolam
艾司唑仑
更新于：2024-11-04
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1975-04-25), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C16H11ClN4 |
InChIKeyCDCHDCWJMGXXRH-UHFFFAOYSA-N |
CAS号29975-16-4 |
关联
13
项与 艾司唑仑 相关的临床试验中国健康受试者空腹及餐后状态下单次口服艾司唑仑片的单中心、开放、随机、两制剂、两序列、两周期、双交叉人体生物等效性试验
艾司唑仑片在健康受试者中的随机、开放、两制剂、单次给药、两周期、交叉空腹和高脂餐后状态下的生物等效性试验
A Clinical and Comparative Study with Randomly Selected Samples of the Effect of Abdominal Acupunctre Combined with Estazolam-Withdrawal Therapy on Estazolam Dependent Insomnia with Mild Anxiety and Depression
100 项与 艾司唑仑 相关的临床结果
登录后查看更多信息
100 项与 艾司唑仑 相关的转化医学
登录后查看更多信息
100 项与 艾司唑仑 相关的专利（医药）
登录后查看更多信息
298
项与 艾司唑仑 相关的文献（医药）2024-07-12Zhongguo zhen jiu = Chinese acupuncture & moxibustion
[Clinical effect of the warm acupuncture of Mongolian medicine on insomnia in the elderly and its brain-gut peptide mechanism: a randomized controlled trial].
Article
作者: A, Gula ; Shen, Meihong ; Lv, Hongyan ; Cao, Li ; Yu, Hong
OBJECTIVE:
To observe the clinical effect and safety of the warm acupuncture of Mongolian medicine in treatment of insomnia in the elderly, and to explore its underlying brain-gut peptide mechanism.
METHODS:
Sixty elderly patients with insomnia were randomly divided into a warm acupuncture group and a western medication group, 30 cases in each group. In the warm acupuncture group, the warm acupuncture of Mongolian medicine was operated at Dinghuixue (at the center of the vertex, the crossing site of the anterior midline and the line connected the upper edges of two ear apexes), Heyixue (at the depression of the spinous process of the 7th cervical vertebra) or Xinxue (at the depression of the spinous process of the 6th thoracic vertebra) in each treatment. Only one of the above points was selected and stimulated for 20 min one treatment and the three points were used alternatively. The treatment was given once every day or every other day, 3 times a week, and for a total of 3 weeks. In the western medication group, estazolam tablets were administered orally, once a day, 1 mg before bedtime, consecutively for 3 weeks. Before and after treatment, as well as in 1-month follow-up visit after the treatment completion, the scores of the Pittsburgh sleep quality index (PSQI) and the insomnia severity index (ISI) were observed in the two groups. The serum brain-related peptide markers (substance P [SP], neuropeptide Y [NPY], 5-hydroxytryptamine 1A [5-HT1A] and 5-hydroxytryptamine 2A [5-HT2A]) were measured before and after treatment, and the clinical efficacy and safety was evaluated in the two groups.
RESULTS:
After treatment and in follow-up, the scores of sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbance and daytime dysfunction, as well as the total scores of PSQI, and ISI scores were all reduced in the two groups (P<0.05, P<0.01); and the scores in the warm acupuncture group were lower than those of the western medication group (P<0.05, P<0.01). After treatment, the levels of serum SP and 5-HT2A were decreased (P<0.01) and the levels of serum NPY and 5-HT1A were increased (P<0.01) when compared with those before treatment in the two groups. The levels of serum SP and 5-HT2A in the warm acupuncture group were lower than those of the western medication group (P<0.05), and the levels of serum NPY and 5-HT1A were higher than those of the western medication group (P<0.05). After treatment, the total effective rate was 93.3% (28/30) in the warm acupuncture group, which was higher than 83.3% (25/30) of the western medication group (P<0.05). No serious adverse reactions were found in the two groups.
CONCLUSION:
Warm acupuncture of Mongolian medicine can effectively improve the sleep quality of the elderly patients with insomnia, and its mechanism may be related to the regulation of the levels of serum SP, NPY, 5-HT1A and 5-HT2A.
2024-02-16Medicine
Insomnia among coronavirus disease 2019 survivors: A single-center cross-sectional study
Article
作者: Lu, Man-Lu ; Yu, Yan ; Wu, Jing-Lin ; Pan, Lei ; Zhu, Ji-Wei ; Liu, Lu ; Ding, Chang-Ling ; Kong, Gui-Qing ; Lv, Liang-Yan
Since the coronavirus disease 2019 (COVID-19) epidemic, insomnia has become one of the longer COVID-19 symptoms. This study aimed to investigate insomnia among COVID-19 survivors and explore the occurrence and influencing factors of insomnia. A cross-sectional study was performed from December 2022 to February 2023 through an online questionnaire star survey with 8 questions. The insomnia severity index scale (ISI) was used to assess the severity of insomnia. Univariate analysis was used to analyze the factors related to COVID-19 infection. A total of 564 participants (183 males and 381 females) were surveyed in the present study. The prevalence of insomnia was 63.12%. Among these insomnia patients, there were 202 (35.82%) with sub-threshold symptoms, 116 (20.57%) with moderate symptoms, and 38 (6.74%) with severe symptoms. Univariate analysis indicated that there were statistically significant differences in the prevalence of insomnia among COVID-19 survivors of different ages, occupations, and educational levels (P < .05). Of the 356 insomnia patients, 185 (51.97%) did not take any measures against insomnia, while those who took drugs only, physical exercise only, drugs and physical exercise, and other measures were 90 (25.28%), 42 (11.80%), 17 (4.78%), and 22 (6.18%), respectively. Additionally, of the 107 insomnia patients with drug therapy, 17 (15.89%) took estazolam, 16 (14.95%) took alprazolam, 39 (36.45%) took zopiclone, and 35 (32.71%) took other drugs to improve insomnia symptoms. The prevalence of insomnia symptoms remains high among COVID-19 survivors in China. Education level and occupation may be the influencing factors. Unfortunately, most patients with insomnia do not take corresponding treatment measures.
2024-01-01Journal of chromatography. A
Trace analysis of 47 psychotropic medications in environmental samples by ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS)
Article
作者: Xu, Meiying ; Yu, Zhiqiang ; Wang, Anguo ; Zhang, Jinna ; Mai, Zhiyuan ; Hu, Lixin ; Liu, Yousheng ; Lai, Sihua
Psychotropic medications are one of the most prescribed pharmaceuticals in the world. Given their frequent detection and ecotoxicity to the no-target organism, the emission of these medications into environments has gradually draw attention. The study developed a sensitive and reliable analytic method to simultaneously investigate 47 psychotropic medications in four matrices: wastewater, surface water, activated sludge, and sediment by ultra-performance liquid chromatography-electrospray ionization-tandem mass spectrometry (UPLC-ESI-MS/MS). These 47 target analytes include 24 antidepressants, 17 antianxiety drugs, 5 anticonvulsants, and 1 relevant hormone. Solid phase extraction (SPE) was employed to extract analytes from water-phase samples. Ultrasonic Solvent Extraction method with Enhanced Matrix Removal clean-up (USE-EMR) was utilized to extract target compounds from solid-phase samples, which requires more straightforward and convenient procedures than previous methods. The extraction recoveries of all analytes ranged from 80 % to 120 % in these four sample matrices. In this study, The limit of quantitation for 47 psychotropic medications were 0.15 ng/L (estazolam) to 2.27 ng/L (lorazepam), 0.08 ng/L (desvenlafaxine) to 2 ng/L (mianserin), 0.22 ng/g (dry weight, dw) (nordiazepam) to 3.65 ng/g (dw) (lorazepam), and 0.07 ng/g (dw) (carbamazepine) to 2.85 ng/g (lorazepam), in wastewater, surface water, sludge, and sediment, respectively. In addition, the developed method was employed to analyse actual samples in two wastewater treatment plants and their receiving rivers. Carbamazepine, escitalopram, clozapine, desvenlafaxine, diazepam, lamotrigine, sertraline, temazepam, and venlafaxine were nearly ubiquitous in all matrices. Moreover, this study indicated that the inadequate removal efficiencies of psychotropic medications in wastewater treatment plants (WWTPs) had resulted in a persistent discharge of these contaminants from human sources into environments.
100 项与 艾司唑仑 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 焦虑症 | 中国 | 1981-01-01 | |
| 癫痫 | 中国 | 1981-01-01 | |
| 入睡和睡眠障碍 | 日本 | 1975-04-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 36 | Sleep medication (+) | 鏇齋膚膚觸壓選鏇鏇獵(築夢選衊壓餘壓顧餘壓) = 簾構蓋鬱憲鬱蓋醖衊積 窪繭壓齋積網淵遞網醖 (衊製餘鬱鹽觸網衊廠餘, 8.7) 更多 | 不佳 | 2017-10-07 | ||
Sleep medication (-) | 鏇齋膚膚觸壓選鏇鏇獵(築夢選衊壓餘壓顧餘壓) = 壓觸範齋顧繭襯蓋鑰遞 窪繭壓齋積網淵遞網醖 (衊製餘鬱鹽觸網衊廠餘, 8.4) 更多 | ||||||
临床4期 | 30 | benzodiazepine | 憲衊艱襯繭選廠鏇鏇網(襯網醖糧築膚顧齋構範) = 鑰鏇衊夢蓋夢築願範願 積築鹹艱構範衊鑰鹽獵 (網觸鑰膚鹽鹹繭鹽獵夢, 窪築淵製夢積壓艱艱淵 ~ 窪鹹遞餘齋窪簾夢艱構) 更多 | - | 2012-03-26 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用